Stocks Health care NVCR
NASDAQ · Health careNovoCure Ltd (NVCR)
NovoCure Ltd brought in $725.4M of revenue over the twelve months to September 30, 2026, up 12.9% from a year earlier. It posted a net loss of $121.7M. In fiscal 2025 capital spending exceeded operating cash flow by $75.7M. At September 30, 2026 it held $96.7M in cash against $25M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about NovoCure Ltd
- Net worth
- NovoCure Ltd has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $350.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $655.4M (+8.3% year on year), with a net loss of $136.2M. Over the 12 months to September 30, 2026: revenue $725.4M, net loss $121.7M.
- Cash flow
- In fiscal 2025 operations used $49M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- NovoCure Ltd's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What NovoCure Ltd does
NovoCure Ltd is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker NVCR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $655.4M | -$136.2M | -$1.22 | -$75.7M |
| 2024 | $605.2M | -$168.6M | -$1.56 | -$69.2M |
| 2023 | $509.3M | -$207M | -$1.95 | -$100.4M |
| 2022 | $537.8M | -$92.5M | -$0.88 | $9.4M |
| 2021 | $535M | -$58.4M | -$0.56 | $58.6M |
| 2020 | $494.4M | $19.8M | $0.18 | $84.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NVCR ranks in Health care
Latest SEC filings
What NovoCure Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Passive stake changed SCHEDULE 13G/A
- November 9, 2026
- October 29, 2026
- October 29, 2026
- October 29, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 16% to $193.4M versus the same quarter last year; diluted EPS -$0.09 versus -$0.33.
- October 1, 2026
- September 9, 2026
- September 1, 2026Other event 8-K
- July 23, 2026
- July 23, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 16% to $183.6M versus the same quarter last year; diluted EPS -$0.13 versus -$0.36.
Insider trades
What the people running NovoCure Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $8.7K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 2, 2026 | Puri Michal NathChief Human Resources Officer | Sold | 660 | $8.7K |
| June 30, 2026 | Danziger AsafDirector | Received as pay | 268 | $3K |
| June 30, 2026 | Leonard Frank XChief Executive Officer | Received as pay | 1,905 | $21.2K |
| June 30, 2026 | Ben Arye BarakGeneral Counsel | Received as pay | 1,299 | $14.5K |
| June 30, 2026 | Puri Michal NathChief Human Resources Officer | Received as pay | 1,905 | $21.2K |
| June 4, 2026 | Leonard Frank XChief Executive Officer | Sold | 34,273 | $614.6K |
| June 3, 2026 | Hilleman Jeryl LDirector | Received as pay | 11,610 | - |
| June 3, 2026 | Leung GabrielDirector | Received as pay | 11,610 | - |
Who owns NVCR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Soleus Capital Master Fund, L.P.13G, passive with 5 related filers | 8.1% | November 9, 2026 |
| Vanguard Portfolio Management13G, passive | 5.57% | April 28, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 216 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 17,373,078 | +303,929 |
| BlackRock, Inc. | 13,413,699 | +219,934 |
| Soleus Capital Management, L.P. | 9,913,401 | -578,990 |
| Vanguard Portfolio Management LLC | 6,272,490 | +20,789 |
| Vanguard Capital Management LLC | 4,903,633 | +221,569 |
| Morgan Stanley | 4,522,389 | -19,137 |
| State Street Corp | 2,866,546 | +304,729 |
| Geode Capital Management, LLC | 2,798,351 | +286,644 |
| Wells Fargo & Company | 2,528,093 | -423,144 |
| Quantinno Capital Management LP | 2,223,455 | -263,921 |
| Renaissance Technologies LLC | 1,951,911 | +400,357 |
| Jpmorgan Chase & Co | 1,671,082 | +740,916 |
| Healthcare of Ontario Pension Plan Trust Fund | 1,385,600 | +659,200 |
| Palo Alto Investors LP | 1,280,439 | 0 |
| Nuveen, LLC | 1,232,087 | +249,734 |
| Jacobs Levy Equity Management, Inc | 1,164,072 | -167,420 |
| Empowered Funds, LLC | 1,154,431 | new |
| Aqr Capital Management LLC | 1,102,131 | +827,199 |
| Dimensional Fund Advisors LP | 1,091,946 | +131,890 |
| D. E. Shaw & Co., Inc. | 1,022,480 | +375,418 |
Insiders
18 insiders reported holding 3,171,268 shares in total, about $40.9M at the last price.
| Holder | Shares |
|---|---|
| Leonard Frank XChief Executive Officer | 461,425 |
| Cordova AshleyFormer Chief Executive Officer | 422,570 |
| Danziger AsafDirector | 416,742 |
| Doyle William FExecutive Chairman, Director | 328,397 |
| Weinberg UriChf Medical and Innovation Ofr | 267,190 |
| Ben Arye BarakGeneral Counsel | 243,752 |
| Vernon W AnthonyDirector | 209,267 |
| Puri Michal NathChief Human Resources Officer | 202,567 |
| Brackmann ChristophChief Financial Officer | 182,842 |
| Leupin NicolasFormer Chief Medical Officer | 102,979 |
Questions about NVCR
What does NovoCure Ltd do?
NovoCure Ltd is a company in the Health care sector, listed on NASDAQ as NVCR. Its shares trade on NASDAQ under the ticker NVCR.
What is NovoCure Ltd's net worth?
NovoCure Ltd has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $350.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is NovoCure Ltd profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $121.7M on revenue of $725.4M.
How much revenue does NovoCure Ltd make?
Over the twelve months to September 30, 2026 NovoCure Ltd reported revenue of $725.4M. That is 12.9% more than a year earlier.
When did NovoCure Ltd last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 9, 2026.
When is NovoCure Ltd's next earnings report?
NovoCure Ltd's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare NVCR with
Follow NVCR
Get an email when NovoCure Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values NovoCure Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.